Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts

1 week ago 11

Attiya Zainib

Tue, January 27, 2026 astatine 8:46 AM CST 3 min read

Chautauqua Capital Management, a part of Baird Asset Management, is simply a boutique concern steadfast that released its fourth-quarter 2025 capitalist missive for the “Baird Chautauqua International and Global Growth Fund”. A transcript of the missive tin beryllium downloaded here. Global equities finished 2025 strongly, with planetary markets delivering their widest outperformance versus U.S. equities since the Global Financial Crisis, aided by a weaker dollar and improving commercialized conditions. In Q4 2025, the Baird Chautauqua International Growth Fund returned +0.11%, lagging the MSCI ACWI ex-U.S. Index’s +5.05%, portion the Global Growth Fund gained +4.18%, outperforming its MSCI ACWI Index® ND’s +3.29%, arsenic worth and cyclical enactment weighed connected growth-oriented portfolios. Despite near-term headwinds from assemblage rotations and Greater China profit-taking, the money remains focused connected high-quality businesses with beardown currency flows and equilibrium sheets, supported by charismatic planetary valuations and a much favorable macro backdrop heading into 2026.

In its fourth-quarter 2025 capitalist letter, Baird Chautauqua International and Global Growth Funds highlighted stocks specified arsenic Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is simply a biotechnology person focused connected processing innovative medicines for superior diseases. The one-month instrumentality of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was astir -0.30%, and its shares stay astir 12.42% supra their 52-week precocious arsenic of the latest session. On January 26, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) banal closed astatine astir $762.65 per share, with a marketplace capitalization of astir $81.779 billion.

Baird Chautauqua International and Global Growth Funds stated the pursuing regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN):

"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported beardown 3Q25 results with some top- and bottom-line beats driven by Dupixent and Eylea HD. Issues with Eylea HD third-party manufacturing volition apt beryllium resolved successful 2026. In addition, determination volition beryllium important pipeline information readouts successful 2026."

Regeneron (REGN) Posts Solid Q3 Results, Eyes 2026 Pipeline Catalysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 78 hedge money portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) astatine the extremity of the 3rd quarter, which was 73 successful the erstwhile quarter. While we admit the hazard and imaginable of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.